Chelsie Derman

A 5-year follow-up showed 76% of delabeled children reused the previously avoided antibiotic without significant adverse reactions.

A phase 1b/2a study showed CM326 significantly improved nasal polyp scores; baseline plasma TSLP levels ≥ 330 fg/mL may predict treatment response.

New research links soft drink consumption to depression, revealing gut microbiota changes as a potential mediator, particularly in women.

Study finds heart rate deceleration within 45 seconds of iTBS may serve as a biomarker for improved depression outcomes, regardless of stimulation site.

A new digital therapeutic, CT-155, shows promise in reducing negative symptoms of schizophrenia.

Roche’s Elecsys pTau181 blood test helps primary care clinicians rule out Alzheimer’s amyloid pathology in patients with cognitive symptoms.

Oticara’s intranasal steroid cream meets primary endpoints in phase 2 trial, providing rapid, durable symptom relief for post-surgical chronic rhinosinusitis.

A 9-year real-world study found allergen immunotherapy reduced medication use and asthma flare-ups, showing lasting control of allergic rhinitis.

New research links early baby formula feeding to increased risks of peanut and multiple food allergies, highlighting the importance of colostrum.

FDA approves UZEDY, a long-acting risperidone injection, for adults with bipolar I disorder.

Patients with allergic rhinitis report less satisfaction with oral antihistamines than intranasal corticosteroids or combination therapies.

A recent study reveals that small intestinal dilation significantly contributes to abdominal symptoms in adults with Food-Protein-Induced Enterocolitis Syndrome (FPIES).

A new trial reveals that educational interventions significantly enhance pediatricians' adherence to guidelines for early peanut introduction.

Subcutaneous Dpg-pol-cat significantly improved the quality of life and reduced medication use in adults with moderate to severe cat allergy.

Emerging research highlights the critical link between sleep quality and cardiovascular health.

Explore the latest advancements in psychiatry, including FDA updates, emerging therapies, and promising clinical trial results for mental health treatments.

Explore the latest advancements in allergy and immunology, including new therapies, FDA approvals, and innovative clinical strategies for improved patient care from Q3.

This month in review focuses on innovative therapies in psychiatry, including MM120 for anxiety and ammoxetine for depression, as well as providing safety insights.

This month in review features the latest breakthroughs in allergy treatments, including innovative therapies for cat and peanut allergies.

The FDA has approved remibrutinib, a new oral treatment for chronic spontaneous urticaria, offering hope for patients unresponsive to antihistamines.

A study found 3% hypertonic saline nasal irrigation reduced symptoms in allergic rhinitis but offered no significant advantage over isotonic saline.

A phase 2 trial demonstrated the effectiveness, safety, and tolerability of ammoxetine (40 and 60 mg) in patients with major depressive disorder.

Weeks discusses how tirzepatide is impacting treatment strategies for obstructive sleep apnea and driving collaboration across specialties.

A meta-analysis confirmed CARATkids as a reliable tool for assessing asthma and allergic rhinitis control in children aged 6–12 years.

FDA approval of tirzepatide for OSA sparks a surge in referrals as experts highlight weight loss benefits, symptom relief, and patient selection.

CBT-I improved sleep outcomes and achieved 54% remission in patients with chronic pain, cancer, cardiovascular disease, and other chronic conditions.

In a study, the prevalence of transthyretin cardiac amyloidosis reached 17% in Black men over 75 years old.

AKINESIS study finds kidney tubule biomarker IGFBP‑7 predicts 1-year death and heart failure readmission in acute heart failure patients.

Research suggests emergency department–discharged children rarely return within 7 days, questioning routine corticosteroid use for mild-to-moderate reactions.

EADV 2025 findings show patients with atopic eczema face greater risks of depression, anxiety, sleep disorders, and stigmatization.